LifeVantage (LFVN) insider report: PRSUs convert; Kristen Cunningham sells 21,801 shares
Rhea-AI Filing Summary
Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.
Positive
- Converted PRSUs to common stock totaling 17,752 and 26,150 units, increasing equity alignment with shareholders
- Participated in ESPP with a purchase of 254 shares, indicating continued employee ownership
- Disclosures reference grant dates and one-for-one conversion, improving transparency
Negative
- Sold 21,801 shares at $13.10, representing insider liquidity that partially reduces holdings
- Beneficial ownership figures vary by line (134,357 to 160,507), which may require careful reconciliation by investors
Insights
TL;DR: Insider activity shows mixed transactions: PRSU conversions and an ESPP buy alongside a notable open-market sale.
The filing documents non-cash PRSU conversions totaling 43,902 units (17,752 + 26,150) that convert one-for-one into common shares, increasing share exposure without cash outlay. The ESPP purchase of 254 shares is routine employee participation. The sale of 21,801 shares at $13.10 partially offsets those increases and represents realized insider liquidity. Overall, the activity is typical compensation-related vesting plus a voluntary sale and does not by itself indicate a material change to company fundamentals.
TL;DR: Transactions appear consistent with executive compensation vesting and routine insider selling; disclosures are timely and complete.
The report identifies PRSU grants from prior years (grants dated Aug 24, 2023 and Aug 26, 2024) that vested or converted on 08/31/2025 and are disclosed as required. The presence of an ESPP purchase and a contemporaneous open-market sale suggests portfolio rebalancing or personal liquidity rather than governance concerns. The Form 4 is signed via power of attorney and includes explanatory footnotes about grant dates and one-for-one conversion, aligning with standard disclosure practice.